MicroRNA‐21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2‐positive metastatic breast cancer

Breast cancer is the second most common cancer diagnosed worldwide. Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer represents about 20% to 30% of all breast cancers. Trastuzumab is used in the treatment of HER2‐positive breast cancer. MicroRNA‐21 (miR‐21) is an oncomiR that a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular biochemistry 2019-03, Vol.120 (3), p.3459-3466
Main Authors: Badr, Marwa, Said, Hebatallah, Louka, Manal L., Elghazaly, Hesham A., Gaballah, Ahmed, Atef Abd El Mageed, Mai
Format: Article
Language:English
Subjects:
Antisense oligonucleotides
Breast cancer
Cancer
Epidermal growth factor
ErbB-2 protein
Gene expression
Growth factors
human epidermal growth factor receptor 2
Immunotherapy
Metastases
Metastasis
MicroRNAs
microRNA‐21
miRNA
Monoclonal antibodies
Oligonucleotides
Patients
Ribonucleic acid
RNA
Statistical analysis
Targeted cancer therapy
Therapy
Trastuzumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is the second most common cancer diagnosed worldwide. Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer represents about 20% to 30% of all breast cancers. Trastuzumab is used in the treatment of HER2‐positive breast cancer. MicroRNA‐21 (miR‐21) is an oncomiR that acts by inhibiting many tumor‐suppressor genes. We analyzed the relative expression levels of serum miR‐21 in 20 HER2‐positive metastatic breast cancer patients before and after 3 months of treatment with trastuzumab. miR‐21 levels decreased with a high significant difference after trastuzumab therapy (P = 0.001). Although miR‐21 expression levels were lower in responders than in nonresponders, the difference was not statistically significant ( P = 0.6). Our results demonstrated a significant negative correlation between its basal expression, expression levels after treatment, and time to progression ( P = 0.03 and 0.01, respectively). These results make miR‐21 a potential prognostic factor for HER2‐positive metastatic breast cancer patients. Additionally, it can be an interesting potential target in therapy using antisense oligonucleotides for miR‐21. microRNA‐21 (miR‐21) a potential prognostic factor for human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer patients. Additionally, it can be an interesting potential target in therapy.
ISSN:0730-2312
1097-4644
DOI:10.1002/jcb.27620